Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: Preference for a neutral group in the S1 pocket

Journal of Medicinal Chemistry

Volumn 46, Issue 5, 2003, Pages 685-690

  Maignan, Sébastien ^a   Guilloteau, Jean Pierre ^a   Choi Sledeski, Yong Mi ^a,b   Becker, Michael R ^a,b   Ewing, William R ^b,c   Pauls, Henry W ^a,b   Spada, Alfred P ^b,d   Mikol, Vincent ^a  

^a SANOFI   (France)

^b Aventis Pharmaceuticals   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDINE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CARBONYL DERIVATIVE; CHLOROBENZOTHIOPHENE; CHLOROTHIOPHENE; OXYGEN DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERAZINE INHIBITOR; RPR 128515; RPR 132747; RPR 200095; RPR 208944; RPR 209685; SERINE PROTEINASE; SULFONE DERIVATIVE; SULFONYLPIPERAZINONE; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; COMPLEX FORMATION; COVALENT BOND; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG PROTEIN BINDING; ELECTRICITY; HUMAN; HUMAN CELL; HYDROGEN BOND; INHIBITION KINETICS; OPTICAL RESOLUTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

BINDING SITES; FACTOR XA; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PIPERAZINES; PROTEIN BINDING; SERINE PROTEINASE INHIBITORS;

EID: 0037468471     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0203837     Document Type: Article

References (25)

1. Leung, D.; Abbenante, G.; Fairlie, D. P. Protease inhibitors: current status and future prospects. J. Med. Chem. 2000, 43, 305-341.
2. Ewing, W. R.; Pauls, H. W.; Spada, A. P. Progress in the design ofinhibitors of coagulation factor Xa. Drugs Future 1999, 24 (7), 771-787.
3. Prager, N. A.; Abendschein, D. R.; McKenzie, C. R.; Eisenberg, P. R. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 1995, 92, 962-967.
4. Kaiser, B. Thrombin and factor Xa inhibitors. Drugs future 1998, 23, 423-436.
5. Adang, A. E. P.; Rewinkel, J. B. M. A new generation of orally active antithrombotics: comparing strategies in the GPIIb/IIIa, thrombin and factorXa areas. Drugs future 2000, 25, 369-383.
6. Padmanabhan, K.; Padmanabhan, K. P.; Tulinsky, A.; Park, C. H.; Bode, W.; Huber, R.; Blankenship, D. T.; Cardin, A. D.; Kisiel, W. Structure of human des(1-45) factor Xa at 2.2 Å. J. Mol. Biol. 1993, 232, 947-966.
7. Sanderson, P. E. J.; NaylorOlsen, A. M. Thrombin inhibitor design. Curr. Med. Chem. 1998, 5, 289-304.
8. (a) Brandstetter, H.; Kühne, A.; Bode, W.; Huber, R.; von der Saal, W.; Wirthensohn, K.; Engh, R. A. X-ray structure of the active site-inhibited clotting factor Xa. J. Biol. Chem. 1996, 271, 29988-29992.
9. (b) Kamata, K.; Kawamoto, H.; Honma, T.; Iwama, T.; Kim, S.-H. Structural basis for chemical inhibition of human blood coagulation factor Xa. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 6630-6635.
10. (c) Nar, H.; Bauer, M.; Schmid, A.; Stassen, J.-M.; Wienen, W.; Priepke, H. W. M.; Kauffmann, I. K.; Ries, U. J.; Hauel, N. H. Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors. Structure 2001, 9, 29-37.
11. (d) Matter, H.; Defossa, E.; Heinelt, U.; Blohm, P.-M.; Schneider, D.; Müller, A.; Herok, S.; Schreuder, H.; Liesum, A.; Brachvogel, V.; Lönze, P.; Walser, A.; Al-Obeidi, F.; Wildgoose, P. Design and quantitative structure activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa. J. Med. Chem. 2002, 45, 2749-2769.
12. 1 Ligand. J. Med. Chem. 2003, xx, xxxx.
13. (b) Maignan, S.; Guilloteau, J.-P.; Pouzieux, S.; Choi-Sledeski, Y. M.; Becker, M. R.; Klein, S. I.; Ewing, W. R.; Pauls, H. W.; Spada, A.; Mikol, V. Crystal structures of human Factor Xa complexed with potent inhibitors. J. Med. Chem. 2000, 43, 3226-3232.
14. Allen, F. H.; Hoy, V. J. The Cambridge Structural Database System. International Tables for X-ray Crystallography, Volume F: Protein Crystallography; Kluwer Academic Publishers: Dordrecht, The Netherlands, 2000.
15. Stewart, J. J. P. MOPAC: a semi-empirical molecular orbital program. J. Comput. Aided Mol. Des., 1990, 4 (1), 1-105.
16. Katz, B. A.; Sprengeler, P. A.; Luong, C.; Verner, E.; Elrod, K.; Kirtley, M.; Janc, J.; Spencer, J. R.; Breitenbucher, J. G.; Hui, H.; McGee, D.; Allen, D.; Martelli, A.; Mackman, R. L. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets. Chem. Biol. 2001, 8 (11), 1107-1121.
17. Dunitz, J. D. The cost of bound water in crystals and biomolecules. Science 1994, 264, 670-672.
18. Dougherty, D. A. Cation-π interactions in chemistry and biology: a new view of benzene, Phe, Tyr and Trp. Science 1996, 271, 163-168.
19. Gallivan, J. P.; Dougherty, D. A. Cation-π interactions in structural biology. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9459-9464.
20. Tucker, T. J.; Brady, S. F.; Lumma, W. C.; Lewis, S. D.; Gardell, S. J.; Naylor-Olsen, A. L.; Yan, Y.; Sisko, J. T.; Stauffer, K. J.; Lucas, B. J.; Lynch, J. J.; Cook, J. J.; Stranieri, M. T.; Holahan, M. A.; Lyle, E. A.; Baskin, E. P.; Chen, I. W.; Dancheck, K. B.; Krueger, J. A.; Cooper, C. M.; Vacca, J. P. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position. J. Med. Chem. 1998, 41, 3210-3219.
21. Leslie, A. G. W. Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography; Daresbury Lab Eds.: Daresbury, U.K., 1992; No. 26.
22. Collaborative Computational Project, Number 4. "The CCP4 Suite: Programs for protein Crystallography". Acta Crystallogr. 1994, D50, 760-763.
23. Brünger, A. T. X-PLOR, A System for X-ray Crystallography and NMR, version 3.1; Yale University Press: New Haven, CT, 1992.
24. Ewing, W. R.; Becker, M. R.; Choi-Sledeski, Y. M.; Pauls, H. W.; He, W.; Condon, S. M.; Davis, R. S.; Hanney, B. A.; Spada, A. P.; Burns, Christopher J.; Jiang, J. Z.; Li, A.; Myers, M. R.; Lau, W. F.; Poli, G. B. Substituted piperazinone derivatives and other oxoazaheterocyclyl compounds useful as factor Xa inhibitors. PCT Int. Appl. WO 99-US1682 19990127, 1999.
25. Bostwick, J. S.; Bentley, R.; Morgan, S.; Brown, K.; Chu, V.; Ewing, W. R.; Spada, A.; Pauls, H.; Perrone, M.; Dunwiddie, C. T.; Leadley, R. J. RPR120844, a novel specific inhibitor of coagulation factor Xa inhibits venous thrombosis in the rabbit. Thromb. Haemostasis 1999, 81, 157-160.